ANRF unveils patient-capital plan to lift India’s R&D spend to 3% GDP

India’s national research foundation has sketched a patient-capital model to push the country’s R&D expenditure toward 3% of GDP. Speaking to a publication, the CEO outlined an architecture that pairs private investment with open IP licensing and national mission programmes, aiming to cut the decades-long wait for the country to reach global R&D benchmarks.

The plan arrives as the ₹1 lakh crore Research, Development and Innovation (RDI) Fund begins deploying capital: ₹7,131 crore has already been committed to 19 VC funds and research organisations, according to StartupReader’s 14 October coverage. That cohort is expected to focus on deep-tech and semiconductor startups, sectors where the country has struggled to match the scale or ecosystem depth of other major economies.

The framework explicitly targets the tension between short-term venture returns and the decade-long timelines of fundamental research. By licensing IP openly, the organisation hopes to reduce the risk for private investors while still allowing commercialisation through startups. Whether that trade-off will attract enough capital remains an open question; the country’s Q3 2026 funding rose only 5% year-over-year, with investors backing fewer companies, as Inc42 reported on 7 October.

The architecture also aligns with calls for large-scale engineering wins. A prominent industry leader argued earlier this month that the country’s AI ambition hinges on startups achieving milestones substantial enough to compete globally. If the patient-capital model succeeds, it could provide the runway those startups need—but only if they can navigate the country’s practical constraints: budget devices, local languages, and cost structures that have so far limited AI adoption, as StartupReader noted on 30 September.

Sources: yourstory.com